CriticalAntiepileptics. Carboxamide derivatives×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver breaks down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6. Ranolazine is also a substrate of the transporter P-glycoprotein (ranolazine label, US Food and Drug Administration, FDA). Carbamazepine strongly induces CYP3A4 and other liver enzymes, so it can lower the levels of drugs cleared mainly through CYP3A4 (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A4 inducers are expected to make ranolazine ineffective. Rifampicin 600 mg daily lowers ranolazine levels by about 95%, and the ranolazine documents name carbamazepine among these inducers (ranolazine SmPC, European Medicines Agency, EMA, and ranolazine label, FDA). The documents give no figures for carbamazepine itself.
Symptoms
Ranolazine is given to adults with stable angina as an add-on when first-line antianginal drugs do not control symptoms or are not tolerated (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). With carbamazepine, ranolazine is expected to lose its effect (ranolazine SmPC, EMA), so angina attacks (pressing pain behind the breastbone on exertion) may come back or become more frequent. The fall in ranolazine levels itself causes no symptoms. Stopping carbamazepine abruptly can trigger epileptic seizures (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated: ranolazine must not be taken with CYP3A inducers, and the US label names carbamazepine among them (ranolazine label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) says not to use ranolazine in patients taking CYP3A4 inducers, carbamazepine among them, and not to start ranolazine during treatment with them (ranolazine SmPC, European Medicines Agency, EMA). Tell the patient that ranolazine must not be taken with carbamazepine or other such drugs (ranolazine FDA label). The carbamazepine SmPC does not mention ranolazine. According to it, carbamazepine strongly induces CYP3A4 and can lower the levels of drugs cleared mainly through this enzyme, or even cancel their effect (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not stop carbamazepine abruptly: the SmPC says to withdraw it gradually over 6 months (carbamazepine SmPC, AEMPS). The documents give no interval between stopping carbamazepine and starting ranolazine.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- AEMPS: Ficha técnica: Carbamazepina, Tegretol 200 mg (nº registro 39955), sección 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5